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Abstract
Cardiovascular disease incidence rates have long been known to significantly differ between the
two sexes. Estrogens alone fail to explain this phenomenon, bringing an increasing amount of
attention to the role of androgens. Contrary to what was initially hypothesized, androgens seem
to have an overall cardioprotective effect, especially in men. Recent studies and published data
continue to support this notion displaying a consistent inverse correlation with atherosclerosis
progression and cardiovascular disease both in regressive and prospective study models. Clinical
studies have also revealed what seems to be a differential androgenic effect on various
cardiovascular risk factors between men and women. Further insight indicates that in order to
avoid confusion it may be also preferable to separately examine the effects of endogenous androgen
levels from exogenous testosterone administration, as well as discern the differential results of low
to normal and supraphysiological administration doses. This review summarizes old and recent data
according to the above distinctions, in an attempt to further our understanding of the role of
androgens in cardiovascular disease.
Background
Cardiovascular disease is characterized for displaying a
significant difference in incidence rates between men and
women. Even after adjusting for all major risk factors,
men have a two-fold risk to die from coronary heart dis-
ease compared to women, a fact that remains consistent
across various ethnic and social groups [1]. It was initially
attempted to attribute this phenomenon to a possibly
protective effect of estrogens in the female vasculature.
However, there are several factors arguing against this par-
ticular theory. For example, a more careful study of the
epidemiology of cardiovascular disease reveals that inci-
dence rates in women do not follow the trend of other
estrogen-related diseases, which is to say that they do not
seem to display a distinct break-point after menopause
[2]. In addition, the ongoing debate over the effects of
hormone replacement therapy (HRT) on cardiovascular
events in women [3-5] has further weakened the belief
that estrogens act as the major determinants of gender-
specific differences in cardiovascular event rates. As a
result, researchers in recent years have turned with increas-
ing interest on androgens and the roles that they can play.
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Androgens, like most hormones, are partly difficult to
study due to their physiological concentration variability.
Their serum levels display a circadian and circannual var-
iation [6]. Furthermore, their levels display a steady reduc-
tion with age in both men and women [7-14] which can
act as a confounding factor and has prompted most stud-
ies to include age-adjusted multiple linear regression anal-
ysis for their data. Despite these details however, it is
becoming increasingly apparent that androgens are inher-
ently influential in many aspects of cardiovascular dis-
ease, including both primary pathophysiological
mechanisms and contributing major risk factors.
The aim of this review is to summarize recent findings on
the effects of androgens on most of the aforementioned
components of cardiovascular disease and highlight
points of interest that can help shed some light on the
controversial findings regarding sex steroids and their
effects on the human heart and vasculature.
Androgen levels in men with a history of heart disease
The most obvious starting point in the quest for examin-
ing the role of androgens on cardiovascular disease is
looking for differences in androgen levels between
healthy men and men that already have a history of heart
disease. Based on the assumption that androgens have a
deleterious effect on the male cardiovascular system,
researchers from as early back as 1979 had tried to detect
differences in testosterone levels in men that had recently
presented with acute myocardial infarction. Surprisingly
enough, it was soon noted that testosterone levels tended
to be normal prior to infarction, decreased shortly after-
wards and normalized approximately a year later [15].
Later reviews of published data continue to mention that
in almost half of the studies examined, men with a history
of a coronary artery disease had a higher prevalence of
hypoandrogenemia [16-18]. It was thus assumed that low
testosterone levels can be considered either a protective
factor against myocardial infarction, or a resulting effect
from the stress an acute myocardial infarction submits the
male organism to.
The possibility of a hitherto unknown protective andro-
gen effect against acute cardiovascular events was initially
met with enthusiasm, but a number of prospective cohort
studies quickly dashed that hope since none of them
could establish the predictive value of testosterone levels
for myocardial infarction or stroke after adjusting for
other relevant confounding factors [16,17].
The alternative option that low testosterone levels might
be a consequence of stress was thus examined more
closely. However, this theory could not explain the fact
that testosterone levels remained low several months after
the occurrence of a myocardial infarction. Furthermore,
while one older study among 55 men claimed that testo-
sterone and free testosterone inversely correlated with the
degree of coronary disease after adjusting for age and BMI
(body mass index) [18], a more recent one among 90
patients [8] and another among 403 men [12] found no
such association. What is even more impressive is that,
according to English et al, none of their 17 control
patients that suffered from severe valvular disease, and
were thus under heavy stress from a non-atherosclerotic
heart condition, displayed similarly low levels of testoster-
one. If hypotestosteronemia could be attributed to stress,
then one would at least expect testosterone levels to fur-
ther decrease in more severe cases of coronary disease,
which apparently is not the case. Hopefully future
research will provide more insight into this small conun-
drum.
Endogenous androgen levels and the progression of 
atherosclerosis
Since looking into the level differences in men with an
already existing positive history of heart disease could
yield no conclusive conjecture, researchers shifted their
focus to a more progressive approach of the effects of
androgens in the cardiovascular system. Thus, a large
number of clinical studies have attempted to investigate
the possible effects of endogenous androgen levels on the
progression of various atherosclerotic indices, aspiring to
reveal their involvement in a more ongoing setting.
Unlike in other aspects of androgen action in the vascula-
ture, the resulting data here seem to be more consistent,
attributing androgens with a clearly positive influence on
atherosclerotic outcomes.
Carotid artery intima-media thickness (IMT) estimated
via carotid ultrasonography is one of the most popular
markers used to investigate the progression of atheroscle-
rosis. A number of studies focused on correlating carotid
ultrasonography results with androgenic hormone meas-
urements seem to have reached similar conclusions. In all
cases, subjects located in the higher tertiles for testoster-
one levels corresponded with statistically significant lower
IMT values compared to subjects in the lower testosterone
quartiles. Interestingly enough, this finding persisted in
both genders and was consistent in all patient groups,
including both premenopausal and postmenopausal
women, as well as young and old male adults (see Table
1).
In spite of the fact that androgens are not specific for the
female gender, or perhaps because of it, their influence in
this has been studied in women as well as men. However,
there are few studies examining the effects of endogenous
androgen levels in premenopausal women. Bernini et al
observed that, while androstenedione and free testoster-
one seem to be significantly correlated with carotid IMT
measurements even after adjusting for age and other car-Reproductive Biology and Endocrinology 2009, 7:44 http://www.rbej.com/content/7/1/44
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diovascular factors in postmenopausal women [7,10], this
correlation fails to shine through in the group of premen-
opausal women [7]. Other studies focused on postmeno-
pausal subjects either agreed with these findings [19] or
stressed the importance of total testosterone instead of
androstenedione and free testosterone [20,21], (see Table
2). None of them however disputed that androgenic hor-
mones inversely correlate with carotid atherosclerosis pro-
gression.
Similarly in men, there are several studies that concur in
the protective effect of androgens in the progression of
atherosclerosis and almost all of them indicate either free
serum testosterone or total serum testosterone levels as
the major determining factor, even after adjusting for age
and other risk factors (see Table 3). These include both
population-based cross-sectional [12,22-25] and progres-
sive studies [14], further strengthening their conclusions.
While carotid IMT measurements are indeed very popular,
a few studies have focused on atherosclerotic manifesta-
tions of the aorta instead. Demirbag et al measured the
thoracic aorta intima thickness (TAIT) via transesophageal
echocardiography (TEE) and validated its negative corre-
lation with total serum testosterone [26]. Hak et al inves-
tigated mean hormonal levels in relation to aortic
atherosclerosis using radiographic detection of calcified
deposits in the abdominal aorta as an indicator of the
presence of atherosclerotic lesions [13]. Among the 1032
subjects involved (504 men and 528 women), no associ-
ation was made to dehydroepiandrosterone sulfate
(DHEA-S) levels. There was however a clearly negative
correlation between severe atherosclerosis and both bioa-
vailable and total testosterone levels in men, which
remained even after adjusting for other cardiovascular risk
factors. Among women on the other hand, both bioavail-
able and total testosterone levels seemed to positively cor-
relate with aortic atherosclerosis, but this correlation was
diluted after adjusting for other cardiovascular risk factors.
This could perhaps be linked to the adverse effect of
androgens on the lipid profile in women.
Likewise, English et al focused on coronary angiogram
results [8], making comparisons between men with
ischaemic heart disease (> 75% occlusion in at least one
of the major coronary arteries) and control subjects that
were either healthy or presented with non-atherosclerotic
forms of heart conditions in total a sample of 90 men.
This study also indicated a negative correlation between
free and bioavailable testosterone, as well as the free
androgen index (FAI). After adjusting for age and other
risk factors, only the bioavailable testosterone and FAI
correlations persevered. These findings were somewhat
confirmed by Philips et al, who investigated coronary
artery disease in men that had not previously exhibited
acute ischaemic manifestations and in whom testosterone
and free testosterone levels were found to negatively cor-
Table 1: Various studies continue to support that endogenous androgen levels are inversely correlated with the progression of 
atherosclerosis.
Androgen effects in men Androgen effects in women
Coronary artery atherosclerosis Negative correlation [8,27]
Carotid artery atherosclerosis Negative correlation [12,14,22-25] Negative correlation [7,10,19-21]
Aorta atherosclerosis Negative correlation [13,26] Positive correlation (largely diluted when adjusted for other 
cardiovascular risk factors) [13]
Peripheral vasculature atherosclerosis Negative correlation [24]
Table 2: An overview of the statistically significant negative correlations from various recent study results regarding the effects of 
endogenous androgen levels on carotid IMT measurements in women.
Study Subjects DHEA-S A FT TT
Bernini et al,1999 [7] 101 women SS SS SS -
- 48 postmenopausal - SS SS -
- 53 premenopausal - - - -
Kiechl et al,2000 [9] 379 women -
Bernini et al, 2001 [10] 44 postmenopausal women - SS SS -
Debing et al, 2007 [19] 56 postmenopausal cases and 56 postmenopausal controls - SS SS SS
Golden et al, 2002 [20] 182 postmenopausal cases and 182 postmenopausal controls - - SS
Montalcini et al, 2007 [21] 101 non-obese postmenopausal women SS
DHEA-S = dehydroepiandrosterone sulfate, A = androstenedione, FT = free testosterone, TT = total testosterone, SS = statistically significant, - = 
no correlation or not-statistically significant correlationReproductive Biology and Endocrinology 2009, 7:44 http://www.rbej.com/content/7/1/44
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relate with the angiography findings after adjusting for age
and body mass index (BMI) [27].
The fact remains however that we have yet to determine
which of the aforementioned hormonal measurements
presents with the strongest or more consistent correlation
to any of the above atherosclerotic markers. While all
remained in agreement of the protective effect of andro-
gens in the progression of atherosclerosis, each of the
aforementioned studies indicated a different androgenic
hormone measurement as significantly associated with its
results. This may be attributed to the variability of each of
the patient samples or the array of risk factors used to
adjust these findings and the large divergence in study
designs. It still remains though something that we should
further clarify if we ever plan to use one of these measure-
ments both for research and practical purposes.
Androgens and the vascular tone
Although different in its nature from atherosclerotic pro-
gression per se, the regulation of endothelial function and
vascular tone in general remain an important component
of vascular physiology and predictor of cardiovascular dis-
ease. The mechanisms underlying the pathophysiology of
impaired vascular tone regulation and thus the emergence
of arterial hypertension are very complex and beyond the
scope of this study. It is nevertheless important to attempt
to summarize the more important androgen effects that
have been recently reported.
According to a longitudinal study among 206 men, testo-
sterone levels measured 5–10 years prior proved to be an
independent negative predictor factor for arterial stiffness
after adjusting for other risk factors [28], an early predictor
for systolic hypertension. Testosterone has similarly been
reported to bear both acute and chronic vasodilatory
effects upon various vascular beds. Studies from as early
back as the 1940s report the use of testosterone in order to
improve angina pectoris in men with coronary artery dis-
ease [29]. Indeed, when infused directly into the left coro-
nary artery, testosterone induces vasodilation that
improves the existent coronary flow [6] even if it requires
high supra-physiological doses [30]. Other studies report
that acute and chronic administration of testosterone in
either physiological or supraphysiological doses can
improve exercise-induced ST-segment depression on the
ECG of men with established coronary disease [31]. Ani-
mal model studies also exhibited the same dose-depend-
ent vasodilatory effect on not only isolated coronary, but
also femoral and pulmonary arteries [6].
The rapid onset of testosterone's acute vasodilatory action
and the fact that it was not abolished by flutamide, an AR
(androgen receptor) blocker [6], led to the theory that this
particular effect was not mediated through the AR and its
genomic signaling pathway. This was enhanced by later
data that supported that testosterone's vasodilatory action
was not significantly altered in Tfm (testicular feminized)
mice that express a non-functional AR [32].
The same study however also reported that the added
effect of AR-deficiency and low testosterone levels in Tfm
mice led to impaired endothelial function and voltage-
operated calcium channel (VOCC) activity. While this
argues against the release of endothelium-derived prod-
ucts or the inhibition of VOCCs as the underlying mecha-
nism for testosterone's acute vasodilatory action, it does
have implications for the development of systemic arterial
hypertension.
In concordance with this, another study discovered that
congenital hypogonadal men displayed distinctly
impaired vascular reactivity in resistance arteries, as
opposed to conduit arteries, due to reduced endothelium-
dependent (via reduced NO availability) and endothe-
lium-independent vasodilation [33]. What is more
impressive is that prolonged testosterone replacement
therapy in those men further impaired endothelium-
Table 3: An overview of the statistically significant negative correlations from various recent study results regarding the effects of 
endogenous androgen levels on carotid IMT measurements in men.
Study Subjects DHEA DHEA-SF T T T
Kiechl et al, 2000 [9] 371 men -
Van de Beld et al, 2003 [12] 403 elderly men - - SS
- 139 with CVD - - SS
- 263 without CVD - - SS
Muller et al, 2004 [14] 195 elderly men SS -
De Pergola et al, 2003 [22] 127 overweight and obese young men SS
Makinen et al, 2005 [23] 96 andropausal and 140 normal elderly men SS
Yang et al, 2005 [24] 70 elderly men (38 cases and 32 controls) SS -
Svartberg et al, 2006 [25] 1482 men with or without CVD - - SS
DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulfate, FT = free testosterone, TT = total testosterone, SS = statistically 
significant, - = no correlation or not-statistically significant correlationReproductive Biology and Endocrinology 2009, 7:44 http://www.rbej.com/content/7/1/44
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dependent vasodilation by completely removing all avail-
able NO. This is in full disagreement with its effects in
eugonadal men, which means that more research is
needed in order to better understand the way that chronic
testosterone deprivation impairs vascular tone regulation.
Associating androgens with various risk factors
In addition to their effects on the progression of athero-
sclerosis in general, clinical studies have also attempted to
separately investigate the relationship between androgens
and some of the major risk factors that are often being
adjusted for. These mostly include cross-sectional studies
that attempt to correlate various hormone levels with a
wide set of well established cardiovascular risk factors. To
avoid any confusion, these should be differentiated from
studies that investigate exogenous testosterone adminis-
tration or special conditions which result in supraphysio-
logical endogenous androgen levels, since it has been
argued that the effects of androgens may vary in these
cases.
It is mostly agreed upon that androgens have a favorable
effect on cardiovascular risk factors in men [1,16]. Newer
studies continue to reaffirm this observation. One obvi-
ous example is the make-up of a patient's lipid profile.
Although not always reaching the threshold of statistic
significance, a variety of recent studies among men with or
without a history of cardiovascular disease continue to
present data on the positive effect of androgens on the
male lipid profile, mainly associating total testosterone
measurements and the free androgen index with HDL
(high-density lipoprotein) and triglyceride levels [11,25]
(see Table 4). Similar data also exist for other risk factors,
such as high arterial blood pressure and diabetes. These,
however, apparently also display significant correlation
with dehydroepiandrosterone (DHEA) and dehydroepi-
androsterone sulfate (DHEA-S) in a similarly protective
fashion [9,13,25,34] (see Table 4).
Unfortunately, the same protective effect does not extend
to the female population. Contrary to men, higher endog-
enous testosterone levels have been claimed to have an
adverse effect on women's lipid profile [16]. Indeed,
newer studies seem to be in agreement, since total serum
testosterone levels and FAI in particular have been associ-
ated with higher total cholesterol, LDL cholesterol and
triglycerides on one hand, and lower HDL cholesterol lev-
els on the other [19,35,36] (see Table 5). Furthermore,
although lacking an adverse correlation, the androgen
protective effect regarding arterial blood pressure and dia-
betes fails to shine through among female subjects
[9,10,13,19,37] (see Table 5).
An interesting observation at this point is the apparent
effect of androgens on Lp(a) (lipoprotein a). Lp(a) is con-
sidered an independent risk factor for cardiovascular dis-
ease and is distinctly known for its strong genetic
component. Admittedly, at least one study among women
has failed to establish a relationship between endogenous
testosterone concentrations and Lp(a) levels [36]. We
should note however that GnRH (gonadotrophin-releas-
ing hormone) antagonists or GnRH agonist administra-
tion in doses that artificially suppress androgen
production in men can apparently lead to a severe Lp(a)
increase [16,17]. A similarly inverse relationship has also
been shown between androgens and plasminogen activa-
tor inhibitor-1 (PAI-1), fibrinogen and other prothrom-
botic factors [16,17,38], rounding up the cardioprotective
effects of endogenous androgens on the major compo-
nents of the basic risk profile for heart disease.
Androgens are further related to another very significant
cardiovascular risk factor: obesity. Morbid obesity in men
has been associated with decreased androgen levels, while
serum testosterone levels in general inversely correlate
with visceral fat mass [16,17,29,38]. These observations
went hand in hand with the implication of low androgen
levels in insulin resistance, setting the prerequisites for
associating androgens with the metabolic syndrome. It
has yet to be determined however whether the relation-
ship described is one of cause or effect. Some have argued
that many free testosterone concentration measurements
use a tracer analogue method that is affected by SHBG (sex
hormone-binding globulin) levels, which in turn are
decreased by obesity and high insulin concentrations
[17,29,38]. Others claim that low androgen levels in
Table 4: The effect of androgens on the lipid profile and other risk factors in men.
Tchole HDL LDL TG Blood pressure Postload insulin Diabetes
DHEA - [34] - [34] ↓ [34] ↓ [34]
DHEA-S - [13,34] - [13,34] ↓ [34]
- [13]
- [13] ↓ [9,34]
- [13]
T - [11,13] - [11,13]
↑ [25]
- [11] ↓ [11,25] ↓ [25]
- [11–13]
↓ [13] - [12,13]
FAI - [11] ↓ [11] - [11] ↓ [11] - [11]
Tchole = total cholesterol, TG = triglycerides, DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulfate, T = testosterone, 
FAI = free androgen index, ↑ = positive correlation, ↓ = negative correlation, - = no correlation or not statistically significant correlationReproductive Biology and Endocrinology 2009, 7:44 http://www.rbej.com/content/7/1/44
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obese men can be attributed to increased peripheral aro-
matization of androstenedione to estrone by the aro-
matase enzyme [16]. According to at least one study
though, decreased testosterone levels in men with high
body mass index coexisted with significantly decreased
estradiol levels, contradicting the latter theory [8]. And
most importantly, induction of hypotestosteronemia
through the administration of GnRH (gonadotropin-
releasing hormone) agonists has been shown to cause an
increase in body fat mass, establishing the influential role
of androgens in the settings of male obesity.
Indeed, most if not all recent studies confirm that DHEA-
S, free serum testosterone, total serum testosterone and
FAI inversely correlate with not only BMI, but also waist-
to hip ratio (WHR) and total body fat mass measurements
in men [8,10,11,13,22,34] (see Table 6). Similar correla-
tions have also been noted in women, although their sta-
tistic significance is less evident in the female sex
[10,13,37]. The matter of female obesity and androgens
however may still need in-depth research, since observa-
tions made in women with polycystic ovaries syndrome
(PCOS) contradict the previous statement [16,17]. The
coexistence of hyperandrogenemia with obesity and
impaired insulin sensitivity seems telling, but we have yet
to determine whether high androgen levels in themselves
can be considered responsible for obesity and insulin
resistance, or if insulin resistance and the resulting high
insulin concentrations reinforce hyperandrogenemia by
stimulating androgen production in the ovaries. In any
case, one should keep in mind that testosterone concen-
trations in women with PCOS far surpass the physiologi-
cal range and should probably be examined separately
from the effects of low to normal endogenous testoster-
one levels in the general population.
Such an obvious link between androgens and obesity
however raises another interesting question. Could we
perhaps attribute the relationship between androgens and
other risk factors, such as serum lipid concentrations and
insulin sensitivity, to their effects on body fat mass? It
seems entirely logical that lower BMI and WHR measure-
ments might conclude in a more favourable lipid profile,
acting as a confounding factor [39]. However, one might
claim that if that were the main underlying mechanism,
then for all intents and purposes a similar effect should
also appear on the female lipid profile, since androgens
within a normal range inversely correlate with BMI in
women as well. Furthermore, there is evidence that
endogenous androgen levels continue to display the same
correlations with serum lipid levels even after adjusting
for BMI [11]. In other words, the evidence suggest that,
Table 5: The effect of androgens on the lipid profile and other risk factors in women.
Tchole HDL LDL TG Blood pressure Postload insulin G/I Diabetes
DHEA-S - [10,13,35,36] - [10,13,35,36] - [10,35,36] - [35,36] - [10,13,36] - [13] - [10] - [9,13]









- [10,13,19,36] - [13] - [10] - [13,19]
FAI - [35]
↑ [35*,36] (*patients 
only)
↓ [35,36] ↑ [35,36] - [35]
↑ [35*,36] (*patients 
only)
- [36]
Tchole = total cholesterol, TG = triglycerides, G/I = fasting glucose/insulin ratio, DHEA-S = dehydroepiandrosterone sulfate, A = androstenedione, 
FT = free testosterone, TT = total testosterone, FAI = free androgen index, ↑ = positive correlation, ↓ = negative correlation, - = no correlation or 
not statistically significant correlation
Table 6: Linking androgen levels with obesity and body fat distribution
BMI WHR BF
Men Women Men Women Men Women
DHEA ↓ [13,34] ↓ [34]






A ↓ [10] ↓ [10]
FT ↓ [22] - [10] - [10] ↓ [22]
TT ↓ [8,11–13,25] - [10]
↓ [13]
- [13] - [10,13] ↓ [11]
FAI ↓ [11] ↑ [37] ↓ [11]
BMI = Body Mass Index, WHR = Waist-to-Hip Ratio, BF = Body Fat mass, DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone 
sulfate, A = androstenedione, FT = free testosterone, TT = total testosterone, FAI = free androgen index, ↑ = positive correlation, ↓ = negative 
correlation, - = no correlation or not statistically significant correlationReproductive Biology and Endocrinology 2009, 7:44 http://www.rbej.com/content/7/1/44
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despite their link to total body fat mass, the main effect of
androgens is achieved through an independently influen-
tial role.
Finally, an interesting novel notion has recently turned
scientific interest towards the investigation of the possible
immunomodulating effects of testosterone [1]. Yang et al
attempted to study the link between androgens and vari-
ous cytokines among other things in elderly men, and
managed to confirm a statistically significant inverse cor-
relation between free serum testosterone levels and CRP
(C-reactive protein), IL-6 (interleukin-6) and sICAM-1
(soluble intercellular adhesion molecule 1) [24]. This,
confirmed by studies on the implication of androgens in
inflammatory response on a molecular level, indicates a
new field of research concerning their actions in athero-
sclerosis.
Implications for androgen treatment
When looking into the effects of androgens on cardiovas-
cular disease, exogenous testosterone treatment should be
examined separately from the effects of its endogenous
counterpart in order to avoid confusion. The reason for
this is that exogenous intervention seems to wield differ-
ent results from the spontaneous fluctuation of endog-
enous androgen levels. As a result, despite the clearly
cardioprotective actions of androgens in men, if not in
women as well, the matter of testosterone supplementa-
tion is one that requires further research on its own.
Another important point we need to stress is the necessity
to differentiate between testosterone administration in
low-normal and supraphysiological doses, as well as
between hypogonadal and eugonadal men. For example,
when examining the effects of testosterone administration
on plasma lipids, it becomes apparent that supraphysio-
logical doses of androgens lower HDL concentrations and
mildly increase LDL and total serum cholesterol
[16,29,38]. The same applies for anabolic steroid abuse
[16,40]. Most studies however report that physiological
testosterone replacement in hypogonadal men does not
change or only mildly lowers HDL concentration and usu-
ally has no effect or mildly decreases LDL or total serum
cholesterol [29,30,38,41]. In addition, despite its strongly
genetic component, testosterone supplementation has
also been shown to decrease serum levels of Lp(a) in men
[16,29].
Both testosterone administration and anabolic steroid use
seem to decrease PAI-1 and fibrinogen in men and
women, attesting to androgens' anticoagulatory and fibri-
nolytic effects [16,17,29,40]. Things are not as clear how-
ever with serum inflammation markers. A study of
testosterone administration in 65 eugonadal men reports
no correlation with circulating CRP levels [41]. Another
study of DHT (dihydrotestosterone) treatment in 33 men
with partial androgen deficiency also reported no changes
in either CRP, sICAM-1 or sVCAM-1 serum levels [42]. On
the other hand, in a study of gonadotropin treatment
among 29 men with hypogonadotropic hypogonadism,
all inflammation markers measured showed a distinct
decrease [43]. These results should be interpreted with
care though, since gonadotropin administration in these
men is not the same as exogenous testosterone adminis-
tration and its effects may fall within the category of the
effects of endogenous testosterone levels.
It has already been mentioned that obesity has been asso-
ciated with decreased testosterone levels, a relation that
was initially attempted to be attributed to either increased
peripheral aromatization to estrogens or decreased SHBG
concentrations. Further attesting against these two theo-
ries is the observation that testosterone replacement in
hypogonadal men can effectively reduce whole body fat
mass in a dose-dependent manner [1,16,29,38]. Even in
eugonadal men testosterone treatment can have a positive
effect on visceral fat mass. It can also improve insulin sen-
sitivity, but care should be taken to distinguish between
the effects of low and high testosterone doses on insulin
resistance. Testosterone administration can apparently
improve insulin sensitivity and reduce insulin levels in the
case of physiological supplementation, but it can also lead
to increased insulin resistance when attempted in a higher
dosage [29,38]. The implication of anabolic steroids in
increased insulin resistance and altered glucose tolerance
seems to fall within the latter category [40]. As a side
observation, it is interesting to note that a feedback rela-
tionship between insulin and testosterone levels may exist
as well. Insulin infusion in obese men can increase testo-
sterone levels, while increased insulin levels have been
shown to contribute to increased androgen production in
women with PCOS [16,17].
The matter of exogenous androgen administration in
women can also prove fairly interesting. A 20-year obser-
vation study of testosterone administration among 293
female-to-male transsexuals reported no increase in cardi-
ovascular deaths [44] even though they received consider-
ably high testosterone doses. On the other hand, a recent
study among 513 postmenopausal women, 25 of which
reported intramuscular administration of testosterone
along the lines of hormone replacement treatment, found
a marked increase in severe aorta atherosclerosis among
those that had received testosterone treatment [45].
Although there is the distinct difference that testosterone
treatment in the latter study coincided with estradiol
administration which may act as a confounding factor,
the fact remains that, despite its beneficiary effects in men,
testosterone supplementation should be examined sepa-
rately in women.Reproductive Biology and Endocrinology 2009, 7:44 http://www.rbej.com/content/7/1/44
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Finally, it should also be mentioned that Dougherty et al
attempted to investigate an alternative option to outright
testosterone treatment: the administration of anastrozole,
an oral aromatase inhibitor. Anastrozole was able to nor-
malize testosterone levels in hypogonadal men and
reduce estradiol levels. Contrary to testosterone treatment
however, no significant changes in either lipid profile or
inflammation markers were detected, which was partly
attributed to the mixed effects of increasing testosterone
and reducing estradiol levels [46].
Conclusion
After the initial disregard concerning their role in cardio-
vascular disease, androgens are now increasingly attract-
ing scientific interest. A large array of data testifies in favor
of a variety of cardioprotective androgen effects in men
mostly, but in many cases in women as well. Different
endogenous androgenic hormone measurements have
been associated with the progression of atherosclerosis
and an inverse correlation was almost always displayed in
both men and women. On the other hand, total serum
testosterone levels and the free androgen index seem to
differentially associate with various risk factors in men
and women, which mainly consist of various parameters
of the lipid profile, arterial blood pressure, diabetes and
obesity. Following the verified existence of interacting
mechanisms at the molecular level, certain associations
between androgens and circulating inflammatory markers
have been established as well.
In order to avoid confusion, exogenous testosterone treat-
ment should be examined separately from the effects of
endogenous androgen levels. The same applies for differ-
ent levels of administration doses. Testosterone supple-
mentation in low to normal levels in hypogonadal men
has mostly been shown to benefit the subjects receiving it,
although not to the degree perhaps one would expect
from the many positive effects of its endogenous counter-
part. Testosterone administration in supraphysiological
doses however, along with anabolic steroid abuse, seems
to adversely affect both the lipid profile and insulin sensi-
tivity in men. Its effects in women have yet to be
researched in depth, while an attempt to replace testoster-
one treatment with oral aromatase inhibitors failed to
produce any significant results.
In conclusion, it can be claimed beyond doubt that andro-
gens play an active role in the appearance and progress of
cardiovascular disease. As the debate on the role of estro-
gens continues, understanding the minutiae of the impli-
cation of androgens becomes increasingly important,
while by attempting to further clarify the details of that
implication we can also understand the mechanisms
underlying cardiovascular manifestations in general.
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